1. Volume 376, Issue 9747, Pages 1155-1163 (October 2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial 
Prof Gordon JS Rustin, MD, Maria EL van der Burg, MD, Clare L Griffin, MSc, David Guthrie, FRCR, Alan Lamont, FRCR, Prof Gordon C Jayson, FRCP, Gunnar Kristensen, MD, César Mediola, MD, Corneel Coens, MSc, Wendi Qian, PhD, Prof Mahesh KB Parmar, DPhil, Dr Ann Marie Swart, MD 
The Lancet 
Volume 376, Issue 9747, Pages (October 2010)
DOI: /S (10)
Copyright © 2010 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile ULN=upper limit of normal.
The Lancet  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

3. Figure 2 Main outcome measures
Kaplan-Meier plots for (A) overall survival, (B) second-line chemotherapy, (C) third-line treatment or death, and (D) first deterioration in Global Health Score or death. (E) Duration of time spent with good Global Health Score during the first 2 years from randomisation. HR=hazard ratio.
The Lancet  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions

4. Figure 3 Treatment interactions
Data are number of events/number of patients, observed (O) minus expected (E) events, variance, and hazard ratio (HR; 95% CI).
The Lancet  , DOI: ( /S (10) )
Copyright © 2010 Elsevier Ltd Terms and Conditions